Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 2
2013 2
2014 1
2016 1
2017 2
2018 1
2019 2
2020 4
2021 2
2022 2
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Diagnosis and Treatment of AL Amyloidosis.
Palladini G, Milani P. Palladini G, et al. Drugs. 2023 Feb;83(3):203-216. doi: 10.1007/s40265-022-01830-z. Epub 2023 Jan 18. Drugs. 2023. PMID: 36652193 Review.
Systemic light chain (AL) amyloidosis is caused by an usually small B cell clone that produces a toxic light chain forming amyloid deposits in tissue. ...The diagnosis requires demonstration in a tissue biopsy of amyloid deposits formed by im …
Systemic light chain (AL) amyloidosis is caused by an usually small B cell clone that produces a toxic light …
Management of AL amyloidosis in 2020.
Palladini G, Milani P, Merlini G. Palladini G, et al. Blood. 2020 Dec 3;136(23):2620-2627. doi: 10.1182/blood.2020006913. Blood. 2020. PMID: 33270858 Free article. Review.
In amyloid light chain (AL) amyloidosis, a small B-cell clone, most commonly a plasma cell clone, produces monoclonal light chains that exert organ toxicity and deposit in tissue in the form of amyloid fibrils. ...The daratumumab+bortezomib combination is eme …
In amyloid light chain (AL) amyloidosis, a small B-cell clone, most commonly a plasma cell clone, produces monoclonal l …
What is new in diagnosis and management of light chain amyloidosis?
Palladini G, Merlini G. Palladini G, et al. Blood. 2016 Jul 14;128(2):159-68. doi: 10.1182/blood-2016-01-629790. Epub 2016 Apr 6. Blood. 2016. PMID: 27053535 Free article. Review.
Light chain (AL) amyloidosis is caused by a usually small plasma cell clone producing a misfolded light chain that deposits in tissues. ...Staging systems and response assessment based on biomarkers facilitate the design and conduction of clinic …
Light chain (AL) amyloidosis is caused by a usually small plasma cell clone producing a misfolded light chain …
Advances in the treatment of light chain amyloidosis.
Palladini G, Milani P. Palladini G, et al. Curr Opin Oncol. 2022 Nov 1;34(6):748-756. doi: 10.1097/CCO.0000000000000881. Epub 2022 Aug 4. Curr Opin Oncol. 2022. PMID: 35943427 Review.
PURPOSE OF REVIEW: After many years, the management of systemic light chain (AL) amyloidosis is entering the era of evidence-based medicine, with three recently published randomized clinical trials, a regimen (daratumumab, cyclophosphamide, bortezomib, and de …
PURPOSE OF REVIEW: After many years, the management of systemic light chain (AL) amyloidosis is entering the era of evi …
Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis.
Palladini G, Milani P, Malavasi F, Merlini G. Palladini G, et al. Cells. 2021 Mar 4;10(3):545. doi: 10.3390/cells10030545. Cells. 2021. PMID: 33806310 Free PMC article. Review.
Systemic light-chain (AL) amyloidosis is caused by a small B cell, most commonly a plasma cell (PC), clone that produces toxic light chains (LC) that cause organ dysfunction and deposits in tissues. ...It is likely that daratumumab-based regimens will become …
Systemic light-chain (AL) amyloidosis is caused by a small B cell, most commonly a plasma cell (PC), clone that produce …
Ixazomib: an investigational drug for the treatment of lymphoproliferative disorders.
Smolewski P, Rydygier D. Smolewski P, et al. Expert Opin Investig Drugs. 2019 May;28(5):421-433. doi: 10.1080/13543784.2019.1596258. Epub 2019 Apr 13. Expert Opin Investig Drugs. 2019. PMID: 30907163 Review.
Ixazomib is a new, orally administered, reversible proteasome inhibitor which is under investigation for the treatment of refractory/relapsed multiple myeloma (MM), systemic light chain amyloidosis (AL) and Waldenstrom macroglobulinemia (WM). ...We exa …
Ixazomib is a new, orally administered, reversible proteasome inhibitor which is under investigation for the treatment of refractory/ …
Update on the Contemporary Treatment of Light Chain Amyloidosis Including Stem Cell Transplantation.
Abdallah M, Sanchorawala V. Abdallah M, et al. Am J Med. 2022 Apr;135 Suppl 1:S30-S37. doi: 10.1016/j.amjmed.2022.01.011. Epub 2022 Jan 23. Am J Med. 2022. PMID: 35081382 Review.
The management of immunoglobulin light chain (AL) amyloidosis is complex. Emerging data have shown promising results for several novel agents. ...In this review, we summarize data for various therapeutics in different clinical scenarios of AL …
The management of immunoglobulin light chain (AL) amyloidosis is complex. Emerging data have shown promising res …
European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias.
Gavriatopoulou M, Musto P, Caers J, Merlini G, Kastritis E, van de Donk N, Gay F, Hegenbart U, Hajek R, Zweegman S, Bruno B, Straka C, Dimopoulos MA, Einsele H, Boccadoro M, Sonneveld P, Engelhardt M, Terpos E. Gavriatopoulou M, et al. Leukemia. 2018 Sep;32(9):1883-1898. doi: 10.1038/s41375-018-0209-7. Epub 2018 Jul 23. Leukemia. 2018. PMID: 30038381 Free article. Review.
Due to current advances, the European Myeloma Network updated the diagnostic and therapeutic recommendations for patients with Waldenstrom's macroglobulinemia (WM), AL-amyloidosis, monoclonal immunoglobulin deposition disease (MIDD), POEMS syndrome, and pr …
Due to current advances, the European Myeloma Network updated the diagnostic and therapeutic recommendations for patients with Walden …
Novel challenges in the management of immunoglobulin light chain amyloidosis: from the bench to the bedside.
Basset M, Nuvolone M, Palladini G, Merlini G. Basset M, et al. Expert Rev Hematol. 2020 Sep;13(9):1003-1015. doi: 10.1080/17474086.2020.1803060. Epub 2020 Aug 11. Expert Rev Hematol. 2020. PMID: 32721177 Review.
INTRODUCTION: Immunoglobulin light chain (AL) amyloidosis is one of the most frequent systemic amyloidosis in Western countries. It is caused by a B-cell clone producing a misfolded light chain (LC) that deposits in organs. AREAS C …
INTRODUCTION: Immunoglobulin light chain (AL) amyloidosis is one of the most frequent systemic amyloidosis …
Progress in research: Daratumumab improves treatment outcomes of patients with AL amyloidosis.
Hassan H, Anwer F, Javaid A, Hashmi H. Hassan H, et al. Crit Rev Oncol Hematol. 2021 Sep;165:103435. doi: 10.1016/j.critrevonc.2021.103435. Epub 2021 Jul 31. Crit Rev Oncol Hematol. 2021. PMID: 34343658 Review.
Outcomes for patients with systemic light-chain (AL) amyloidosis have improved over the last two decades with timely diagnosis, use of novel chemotherapeutic agents, risk stratification and better patient selection criteria before hematopoietic autologous ste …
Outcomes for patients with systemic light-chain (AL) amyloidosis have improved over the last two decades with timely di …
19 results